Honluten
/ Khavinson-tradition tripeptide (Lys-Glu-Asp); proposed lung tissue bioregulatorALIAS · KEDR · Lys-Glu-Asp-(Arg) · Lung peptide bioregulator
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Khavinson-tradition tripeptide / short-peptide preparation positioned as a lung-tissue bioregulator. The vendor-marketed active is given as Lys-Glu-Asp (KED), with some preparations extended with arginine (KEDR). The class is described in the Russian-origin tissue-specific bioregulator framework from the Saint-Petersburg Institute of Bioregulation and Gerontology.
Honluten is described in vendor materials as a short-peptide preparation built around a Lys-Glu-Asp (KED) core, sometimes extended as KEDR. Within the Khavinson-tradition framework the claim is that the tripeptide regulates lung-tissue gene expression and bronchopulmonary cell function via direct interaction with promoter regions of tissue-relevant genes. The molecular targets have not been independently characterised.
Tier 4. No PubMed-indexed primary literature distinct from class-level Russian reviews. The KED tripeptide motif appears in Khavinson-group reviews of lung and respiratory tissue peptide bioregulators.
No formal human safety database. General class concerns for short-peptide bioregulators (identity, purity, route, vendor manufacturing controls) apply.
Regulatory status
- FDA status:
- Not FDA-approved
The Khavinson school (Saint-Petersburg Institute of Bioregulation and Gerontology) has published an extensive body of work on short-peptide 'bioregulators' derived from animal-tissue extracts, with a unifying claim that tissue-specific tetrapeptides (and shorter motifs) regulate gene expression and tissue-specific cell function. The corpus is Russian-origin and substantially self-cited; independent Western replication of the foundational findings has not been established.
Honluten has a nomenclature variability: KED, KEDR, and longer extensions are sold under similar names. Independent verification of the actual peptide content of vendor preparations is not available in the published record.